Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Positron Emission Tomography01:29

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

LK-1: an investigational therapy targeting hCG-β in metastatic breast, bladder, ovarian, and cervical cancers.

Scientific reports·2026
Same author

Use of cardiac gated computed tomography in the diagnosis of a rare congenital cardiovascular anomaly in an adult alpaca.

Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association·2024
Same author

A k-mer based transcriptomics approach for antisense drug discovery targeting the Ewing's family of tumors.

Oncotarget·2018
Same author

Detection of unique Ebola virus oligonucleotides using fluorescently-labeled phosphorodiamidate morpholino oligonucleotide probe pairs.

Analytical biochemistry·2018
Same author

Invention and Early History of Morpholinos: From Pipe Dream to Practical Products.

Methods in molecular biology (Clifton, N.J.)·2017
Same author

Pharmacokinetic study and evaluation of the safety of taurolidine for dogs with osteosarcoma.

Journal of experimental & clinical cancer research : CR·2014

Related Experiment Video

Updated: Jul 11, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Tumor imaging using technetium-99m bound to pH-sensitive peptides.

John E Mata1, Leslie A Dyal, Margorie E Slauson

  • 1Department of Biomedical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis, Oregon 97331, USA. john.mata@oregonstate.edu

Nanomedicine : Nanotechnology, Biology, and Medicine
|September 29, 2007
PubMed
Summary

Researchers developed a pH-activated peptide (PAP-1) that targets tumors by changing form in acidic tumor environments. This peptide selectively delivers diagnostic and therapeutic agents to solid tumors, offering a new strategy for cancer intervention.

More Related Videos

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

Related Experiment Videos

Last Updated: Jul 11, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

Area of Science:

  • Biochemistry
  • Oncology
  • Biotechnology

Background:

  • Solid tumors exhibit metabolic abnormalities leading to acidic extracellular environments.
  • These acidic tumor regions present a potential target for novel drug delivery systems.

Purpose of the Study:

  • To investigate the potential of pH-activated peptides for selective tumor targeting.
  • To evaluate the efficacy of PAP-1 in delivering payloads to tumors in vitro and in vivo.

Main Methods:

  • Design and synthesis of an 18 amino acid pH-activated peptide (PAP-1) with a transition pH (pT) of 6.4.
  • Labeling PAP-1 with fluorescein and technetium-99m (99mTc).
  • In vitro and in vivo evaluation in two murine cancer models using flow cytometry, fluorescence microscopy, and gamma scintigraphy.

Main Results:

  • PAP-1 demonstrated a pH-dependent transition from a hydrophilic to a lipophilic form.
  • Low pH activated PAP-1, facilitating its penetration into tumor cells and tissues.
  • Successful delivery of fluorescein and 99mTc to tumors was confirmed.

Conclusions:

  • PAP-1 enables selective delivery of macromolecules to tumors by exploiting the acidic tumor microenvironment.
  • This pH-activated peptide technology holds promise for highly specific medical interventions in cancer treatment.